Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25B | P30305 | 1/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.53 |
| ▸ | DRD2 | P14416 | 2/20 | 0.53 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.53 |
| ▸ | DRD4 | P21917 | 2/20 | 0.53 |
| ▸ | HRH2 | P25021 | 2/20 | 0.53 |
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | HTR7 | P34969 | 2/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.53 |
| ▸ | HRH1 | P35367 | 2/20 | 0.53 |
| ▸ | DRD3 | P35462 | 2/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.53 |
| ▸ | HTR2B | P41595 | 2/20 | 0.53 |
| ▸ | HTR6 | P50406 | 2/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20046958 | 0.86 | MAPT (0.60) | CDC25BDRD2DRD3LMNAKDM4E | |
| SCHEMBL20046775 | 0.80 | NSD2 (0.53) | CDC25BDRD2DRD3LMNAMEN1 | |
| SCHEMBL20046757 | 0.77 | MAPT (0.67) | CDC25BLMNAKDM4EMEN1MAPK1 | |
| SCHEMBL22266161 | 0.75 | KCNH2 (0.62) | CHRM2ADRA2ADRD2ADRA2BADRA2C | |
| SCHEMBL11104593 | 0.75 | KDM4E (0.52) | CDC25BCHRM2ADRA2ADRD2ADRA2B | |
| SCHEMBL17250432 | 0.74 | NSD2 (0.63) | CDC25BDRD2DRD4DRD3LMNA | |
| SCHEMBL17250407 | 0.73 | NSD2 (0.67) | CDC25BDRD2DRD3LMNAMEN1 | |
| SCHEMBL13856939 | 0.72 | NSD2 (0.52) | CDC25BCHRM2ADRA2ADRD2ADRA2B | |
| SCHEMBL8250517 | 0.70 | HRH1 (0.68) | CDC25BCHRM2ADRA2ADRD2ADRA2B | |
| SCHEMBL8966405 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459313-B2 | Aziridinyl and amino dimeric naphthoquinone compounds and use for acute myeloid leukemia | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-10-04 | — | — | US | disclosed |
| US-20200283417-A1 | AZIRIDINYL AND AMINO DIMERIC NAPHTHOQUINONE COMPOUNDS AND USE FOR ACUTE MYELOID LEUKEMIA | UNIVERSITY OF MARYLAND, BALTIMORE | 2020-09-10 | — | — | US | disclosed |
| US-20200283417-A1 | AZIRIDINYL AND AMINO DIMERIC NAPHTHOQUINONE COMPOUNDS AND USE FOR ACUTE MYELOID LEUKEMIA | UNIVERSITY OF MARYLAND, BALTIMORE | 2020-09-10 | — | — | US | disclosed |
| WO-2018067842-A1 | AZIRIDINYL AND AMINO DIMERIC NAPHTHOQUINONE COMPOUNDS AND USE FOR ACUTE MYELOID LEUKEMIA | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283417-A1 | AZIRIDINYL AND AMINO DIMERIC NAPHTHOQUINONE COMPOUNDS AND USE FOR ACUTE MYELOID LEUKEMIA | MCL1, NPM1, ABL1 | CDC25B 502/4885CHRM2 2212/4885ADRA2A 1766/4885 |
| US-11459313-B2 | Aziridinyl and amino dimeric naphthoquinone compounds and use for acute myeloid leukemia | MCL1, NPM1, ABL1 | CDC25B 502/4885CHRM2 2212/4885ADRA2A 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.